
    lack of accrual
  
['stage i prostate adenocarcinoma', 'stage ii prostate adenocarcinoma']
['bicalutamide', 'raloxifene hydrochloride']

        Inclusion Criteria:

          -  Histological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical
             stage T1a-T2c and planned for radical prostatectomy

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Platelet count >= 50,000/mm^3

          -  Hemoglobin > 9.0 g/dL

          -  Creatinine =< 2.0 mg/dL

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
             Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active
             treatment and observation), participants must be willing to return to the consenting
             institution for follow-up

          -  Patients must also provide written consent for biospecimens collection on
             Institutional Review Board (IRB) 08-000980

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  History of myocardial infarction =< 6 months, or congestive heart failure requiring
             use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

          -  History of a venous thromboembolic event, cerebrovascular accident (CVA), hepatic
             impairment, or heart failure
      